BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $349,838 | -36.9% | 21,100 | -36.5% | 0.00% | – |
| Q4 2021 | $554,000 | -71.4% | 33,228 | -19.7% | 0.00% | -100.0% |
| Q3 2021 | $1,938,000 | -28.2% | 41,358 | -6.6% | 0.00% | 0.0% |
| Q2 2021 | $2,698,000 | -24.6% | 44,258 | -23.8% | 0.00% | -33.3% |
| Q1 2021 | $3,580,000 | +77.0% | 58,118 | +104.2% | 0.00% | +50.0% |
| Q4 2020 | $2,023,000 | +89.4% | 28,460 | 0.0% | 0.00% | +100.0% |
| Q3 2020 | $1,068,000 | +5.6% | 28,460 | -8.2% | 0.00% | 0.0% |
| Q2 2020 | $1,011,000 | -37.5% | 31,010 | -44.4% | 0.00% | -50.0% |
| Q1 2020 | $1,617,000 | -43.1% | 55,759 | -31.2% | 0.00% | -33.3% |
| Q4 2019 | $2,842,000 | – | 81,096 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |